Africa’s genetic diversity could transform global mental health research

Mental illness is quietly becoming one of Africa’s most pressing health emergencies, and a sweeping new review argues that the continent’s extraordinary genetic diversity may hold the key to understanding psychiatric disorders for the entire world. Writing in Nature Communications, an international team of researchers led by Conrad Iyegbe of the Icahn School of Medicine at Mount Sinai maps out both the scale of the crisis and a roadmap for how African-led neuropsychiatric genetics could reshape precision medicine on a global scale. The message is stark but hopeful: the continent carrying the deepest reservoirs of human genetic variation is also the one most neglected by the very science that could benefit from it most.

The numbers behind the crisis are sobering. Before the COVID-19 pandemic, more than 116 million Africans, roughly 11 percent of the continent’s population, were already living with depression, anxiety, post-traumatic stress disorder or substance-use disorders. Women bear a disproportionate share of this burden, with 66 million meeting criteria for clinical depression. Substance-use disorders are projected to rise by 40 percent by 2030, and Africa’s suicide rate already exceeds the global average, standing at 11 deaths per 100,000 people compared with a global mean of 9. These figures sit atop a health system stretched to breaking point by socio-economic disparity, chronic under-investment and the historically low priority given to mental health in many national budgets.

Service provision tells an even more alarming story. Estimates based on the World Health Organization’s Mental Health Atlas suggest that specialist treatment coverage in sub-Saharan Africa reaches only 10 to 12.8 percent for psychosis, 1.9 to 2.6 percent for bipolar disorder and 2.7 to 3.4 percent for moderate-to-severe depression, implying treatment gaps of roughly 87 to 98 percent. African governments spend on average just US$0.50 per person per year on mental health, a quarter of the minimum recommended for low- and middle-income countries. The workforce deficit is equally severe: only 1.4 mental health professionals serve every 100,000 inhabitants, against a global average of 9. Stigma and pluralistic explanatory models that attribute symptoms to spiritual or supernatural causes can further delay formal help-seeking, particularly where traditional or faith-based providers are the first point of contact.

The economic consequences compound the human toll. Between 2000 and 2015, disability-adjusted life years attributable to mental disorders grew by 52 percent, outpacing the continent’s 49 percent population growth. In 2015 alone, lost productivity from mental disorders amounted to 17.9 million disability years. Rising life expectancy adds another layer of complexity, as non-communicable diseases such as diabetes, cardiovascular disease and cancer increase in parallel, and the relationships run in both directions. Sustained antipsychotic use drives weight gain and metabolic risk; depression undermines adherence to diabetes medication; cardiovascular risk factors predict cognitive decline; and HIV doubles the prevalence of anxiety. This tangled web of mental illness, infectious disease and chronic conditions multiplies healthcare costs and demands integrated rather than siloed policy responses.

Against this backdrop, the review argues that genetics offers an essential and largely untapped dimension. Under the liability-threshold model, the formal framework used to conceptualise how multiple risk factors combine to cause disease, an individual’s underlying genetic liability interacts with environmental stressors such as conflict, malnutrition or toxic stress, pushing some people beyond the threshold of clinical susceptibility while others demonstrate resilience. Understanding this interplay could allow African health systems to stratify risk and target prevention within a precision public health framework, aligning genetic research with the United Nations Sustainable Development Goals and continental policy agendas such as Agenda 2063 and the Africa Health Strategy.

The scientific case rests on the peculiar architecture of psychiatric genetic risk. Over the past two decades, the Psychiatric Genomics Consortium, a network of more than 1,600 investigators in 66 countries that has produced 755 peer-reviewed papers since 2008, has shown that genetic risk for psychiatric disorders is extraordinarily polygenic. For most disorders, risk is distributed across thousands of genomic loci, with each common variant contributing only a tiny increment. Model-based estimates suggest that common variant liability involves roughly 5,600 variants for ADHD, 9,600 for schizophrenia and 14,500 for depression. These diffuse effects coexist with rare copy-number and sequence variants that affect fewer individuals but can raise carrier odds by tens to more than a hundred-fold, a pattern consistent with purifying selection against variants that impair neurodevelopment and reproductive fitness.

Despite these molecular differences, studies repeatedly point to shared biological themes across disorders: synaptic organisation and plasticity, regulation of gene expression during brain development, chromatin remodelling, ion-channel signalling and, particularly in schizophrenia, complement-related synaptic pruning and glutamatergic signalling. Disorder-enriched patterns are emerging too. Autism studies emphasise rare variants in genes such as CHD8, ARID1B, SCN2A and the SHANK family; schizophrenia shows convergence of common and rare variation in synapse biology and the function of complement C4A; bipolar disorder implicates GABAergic interneurons and ion channels such as CACNA1C and CACNB2; and a recent trans-ancestry genome-wide study of depression points to synaptic and receptor-clustering biology. Yet current discoveries still explain only a fraction of the heritability inferred from twin and family studies, with much of the remaining signal likely hidden in non-coding and repetitive DNA, complex structural variation and very rare alleles.

This is precisely where Africa becomes indispensable. In the 1000 Genomes Project, African ancestry genomes showed the highest median number of autosomal single-nucleotide variants, 4.3 million per genome compared with 3.5 to 3.6 million in non-African groupings, reflecting deeper population histories and less severe founder bottlenecks. Shorter haplotype blocks and lower linkage disequilibrium allow association signals to be resolved more precisely. The African Genome Variation Project, sequencing just 320 sub-Saharan Africans, identified 9.5 million novel variants absent from existing global reference catalogues. By contrast, the field’s heavy reliance on European ancestry cohorts has practical consequences: polygenic risk scores lose accuracy when applied to populations unlike the discovery cohort, with the greatest loss occurring in populations of African descent. Treating African ancestry as a homogenous category risks excluding clinically important variation, since genetic structure in eastern and southern Africa correlates with ethnolinguistic diversity.

Momentum is now building on the continent itself. NeuroGAP-Psychosis has completed genomic and phenotypic collections from 42,953 participants in Ethiopia, Uganda, Kenya and South Africa, creating Africa’s single largest collection of neuropsychiatric research data. The South African Xhosa schizophrenia study of 1,826 individuals identified an enrichment of private damaging variants in mutation-intolerant genes, with effect sizes generally larger than those observed in comparable subsamples of a much larger Swedish cohort. NeuroDev has enrolled nearly 5,000 children with autism, ADHD or intellectual disability, identifying pathogenic or likely pathogenic variants in 17 percent of South African and 38 percent of Kenyan probands in its first exome analysis. The NIMH’s Ancestral Populations Network targets 200,000 participants across more than 25 global sites, while Wellcome-funded DepGen Africa is sequencing 8,000 depression cases and 4,000 controls in Nigeria, Ethiopia and Malawi. In North Africa and Sudan, large families and consanguinity offer routes to rare homozygous variants that population-based studies may miss.

The authors argue that turning these sparks into a durable discovery engine requires investment far beyond sample collection. Africa, home to 18.5 percent of the world’s population, accounts for barely 1.3 percent of global research and development expenditure, 2 percent of scientific publications and less than 1 percent of patents. Only South Africa, Kenya and Egypt approach the African Union’s 1-percent-of-GDP research target, and even these trail the spending of BRICS nations, the European Union and the United States. Sequencing capacity remains uneven, though Africa CDC reports that 34 of 55 African Union countries had next-generation sequencing capability in public health laboratories by 2023, up from 7 in 2019. Cost-effective approaches such as blended genome-exome sequencing, which combines low-pass whole-genome with high-depth exome sequencing, are being implemented across multiple African initiatives, while high-throughput whole-genome sequencing protocols have been developed in Nigeria. The Broadband Commission estimates that up to $109 billion will be needed to achieve affordable broadband coverage by 2030, underscoring how genomic medicine depends on connectivity spanning academic, hospital and laboratory settings.

Ultimately, the review frames the next decade as a test of whether African neuropsychiatric genetics can deliver systems of value rather than merely larger sample sizes. The benchmarks include African-initiated multi-country investigations whose results replicate elsewhere, shared phenotype dictionaries and data-access procedures, sequencing and analytic capacity that endures beyond individual grants, and governance frameworks that command public trust. With more than 60 percent of Africa’s population under 25, the demographic dividend is enormous, and programmes such as H3Africa, H3ABioNet and the GINGER training initiative have already seeded a new generation of investigators. Bibliometric trends show African-led psychiatric genetics research attracting increasing citations and appearing in higher-impact journals. If sustained investment in cohorts, informatics, governance and workforce development follows, the continent could move from being a source of genomic insights to a producer and evaluator of genomically-informed medicine, defining globally relevant models of inclusive mental health research and equitable precision public health.

Subject of Research: The state and future of neuropsychiatric genetics research in Africa

Article Title: Neuropsychiatry genetics in Africa

Article References: Iyegbe, C. O., Chaouch, M., Isewon, I., Majara, L., Ayinde, O., A O’Hare, M., Mufford, M., Ubah, O. A., Larnaout, A., Grobler, A.-L., Ramaboli, M., Nto, N. J., Alagbe, E., Toikumo, S., Elmugadam, F., van der Merwe, C., Gureje, O., Bensaid, M., Abdulaziz, M., … Dahdouh, A. (2026). Neuropsychiatry genetics in Africa. Nature Communications, 17(1), Article 10534. https://doi.org/10.1038/s41467-026-78057-z

Image Credits: AI Generated

DOI: 10.1038/s41467-026-78057-z

Keywords: neuropsychiatric genetics, Africa, genomic diversity, mental health, polygenic risk scores, Psychiatric Genomics Consortium, genome-wide association studies, precision public health, NeuroGAP-Psychosis, health policy, sequencing infrastructure, genomic governance